Multivariate‐adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases
暂无分享,去创建一个
Sebastian Schneeweiss | Jerry Avorn | Jeremy A. Rassen | J. Avorn | J. Rassen | S. Schneeweiss | Jeremy A. Rassen
[1] D. Juurlink,et al. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. , 2009, Circulation.
[2] S. Schneeweiss,et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients , 2007, Canadian Medical Association Journal.
[3] E. Pezalla,et al. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. , 2008, Journal of the American College of Cardiology.
[4] Fang Zhang,et al. A distributed research network model for post‐marketing safety studies: the Meningococcal Vaccine Study , 2008, Pharmacoepidemiology and drug safety.
[5] Sebastian Schneeweiss,et al. Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome , 2009, Circulation.
[6] M Blettner,et al. Traditional reviews, meta-analyses and pooled analyses in epidemiology. , 1999, International journal of epidemiology.
[7] B. Hansen. The prognostic analogue of the propensity score , 2008 .
[8] M Alan Brookhart,et al. Osteoporosis Improvement: A Large‐Scale Randomized Controlled Trial of Patient and Primary Care Physician Education , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[9] Robert L Davis,et al. Real-Time Vaccine Safety Surveillance for the Early Detection of Adverse Events , 2007, Medical care.
[10] Vittorio Krogh,et al. Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. , 2006, American journal of epidemiology.
[11] R. D'Agostino. Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .
[12] Donald Rubin,et al. Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.
[13] W. Ray,et al. Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.
[14] Cynthia Dwork,et al. Privacy, accuracy, and consistency too: a holistic solution to contingency table release , 2007, PODS.
[15] S B Thacker,et al. Methods for pooled analyses of epidemiologic studies. , 1994, Epidemiology.
[16] W. Ray,et al. Adjustment for Multiple Cardiovascular Risk Factors Using a Summary Risk Score , 2008, Epidemiology.
[17] Hoeteck Wee,et al. Toward Privacy in Public Databases , 2005, TCC.
[18] C. Friedenreich. Commentary: improving pooled analyses in epidemiology. , 2002, International journal of epidemiology.
[19] Til Stürmer,et al. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. , 2006, Journal of clinical epidemiology.
[20] Dominique Mottier,et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. , 2008, Journal of the American College of Cardiology.
[21] Gary H Lyman,et al. The strengths and limitations of meta-analyses based on aggregate data , 2005, BMC Medical Research Methodology.
[22] B. Strom,et al. PDUFA reauthorization--drug safety's golden moment of opportunity? , 2007, The New England journal of medicine.
[23] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[24] S Shapiro,et al. Confounding by indication? , 1997, Epidemiology.
[25] Sebastian Schneeweiss,et al. Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults , 2004, Circulation.
[26] Richard Platt,et al. Design of a National Distributed Health Data Network , 2009, Annals of Internal Medicine.
[27] J. Avorn,et al. High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data , 2009, Epidemiology.
[28] J. Avorn,et al. A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.
[29] J. Robins,et al. Estimating exposure effects by modelling the expectation of exposure conditional on confounders. , 1992, Biometrics.
[30] Samy Suissa,et al. Immortal time bias in pharmaco-epidemiology. , 2008, American journal of epidemiology.
[31] Vincent Mor,et al. Weaknesses of goodness‐of‐fit tests for evaluating propensity score models: the case of the omitted confounder , 2005, Pharmacoepidemiology and drug safety.
[32] M Alan Brookhart,et al. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. , 2005, American journal of epidemiology.
[33] J. Avorn,et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. , 2005, The New England journal of medicine.
[34] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[35] Lori S. Parsons. Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques , 2001 .